U.S. markets closed
  • S&P 500

    3,785.38
    -33.45 (-0.88%)
     
  • Dow 30

    30,775.43
    -253.88 (-0.82%)
     
  • Nasdaq

    11,028.74
    -149.16 (-1.33%)
     
  • Russell 2000

    1,705.45
    -13.92 (-0.81%)
     
  • Crude Oil

    105.98
    -3.80 (-3.46%)
     
  • Gold

    1,806.90
    -10.60 (-0.58%)
     
  • Silver

    20.24
    -0.50 (-2.40%)
     
  • EUR/USD

    1.0485
    +0.0042 (+0.3984%)
     
  • 10-Yr Bond

    2.9720
    -0.1210 (-3.91%)
     
  • Vix

    28.81
    +0.65 (+2.31%)
     
  • GBP/USD

    1.2172
    +0.0049 (+0.4078%)
     
  • USD/JPY

    135.7000
    -0.8450 (-0.6188%)
     
  • BTC-USD

    18,967.37
    -1,389.63 (-6.83%)
     
  • CMC Crypto 200

    406.30
    -25.17 (-5.83%)
     
  • FTSE 100

    7,169.28
    -143.04 (-1.96%)
     
  • Nikkei 225

    26,393.04
    -411.56 (-1.54%)
     

Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral and a poster presentation on pemvidutide, the Company’s novel, investigational GLP-1/Glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD). The presentations will take place at the NASH-TAG Conference, which is being held January 6-8, 2022, in Park City, Utah. Details for the oral presentation are as follows:

Title:

A placebo-controlled, double-blind, first-in-human study of Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist for the treatment of NASH and obesity

Presenter:

Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc.

Date/Time:

Saturday, January 8, 2022 at 8:10 am Mountain Time

A copy of Dr. Harris’ presentation and poster will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor & Media Contacts:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com